Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Background: Non-invasive brain stimulation (NIBS), especially repetitive transcranial magnetic stimulation (rTMS), is a promising therapeutic tool for managing the psychiatric symptoms of Parkinson's disease (PD). This meta-analysis aims to assess the effect of NIBS on psychiatric symptoms in patients with PD.
Methods: Several electronic databases were systematically searched for relevant literature from inception to October 18, 2021. The therapeutic effects of NIBS were evaluated using a random-effects meta-analysis based on the standard mean difference (SMD) and multivariable-adjusted effect estimates and subgroup analyses. Publication bias and sensitivity analyses were used to explore the sources of heterogeneity.
Results: Finally, 57 and 15 studies with 4,010 participants were obtained from the meta-analysis and systematic review, respectively. Significant differences were found between NIBS and sham-stimulation/placebo participants for depression (SMD = -0.75, 95 % confidence interval [CI]: -0.99 to -0.50, I = 79 %), and rTMS combined with antidepressant therapy and antidepressant alone for depression (SMD = -0.98, 95 % CI: -1.37 to -0.59, I = 87 %) and anxiety (SMD = -1.46, 95 % CI: -2.44 to -0.48, I = 95 %). Meanwhile, lower risks were observed for post-treatment compared with pre-treatment for depression (relative risk [RR] = 0.66, 95 % CI: 0.57-0.76, I = 96 %) and anxiety (RR = 0.66, 95 % CI: 0.60-0.73, I = 67 %).
Conclusions: NIBS can be considered an effective non-pharmacological option for treating PD depression; moreover, rTMS combined with antidepressants was demonstrated to be a useful tool against depression and anxiety in PD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jocn.2022.10.013 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!